Patents by Inventor Hiroyuki Hosokawa

Hiroyuki Hosokawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210364410
    Abstract: To provide a technology for confirming that a desired particle is recovered in single cell analysis. The present technology provides a particle confirming method including a correlating step of correlating ID information possessed by a particle trapped in a well in a particle trapping region with position information of the well, a discharging step of discharging the particle from the well, an ID information acquiring step of acquiring ID information of the particle after the discharging step, and a confirming step of confirming the position of the well in which the particle has been trapped, on the basis of the acquired ID information. In addition, the present technology also provides a particle trapping chip and a particle analyzing system to be used for carrying out the method.
    Type: Application
    Filed: November 11, 2019
    Publication date: November 25, 2021
    Applicant: Sony Corporation
    Inventors: Hiroyuki Hosokawa, Tasuku Yotoriyama, Shin Masuhara, Isamu Nakao
  • Publication number: 20210002692
    Abstract: To provide a method for detecting a target substance by using an interaction through a molecular species having low reactivity, with two types of microparticles as proximity probes. A target substance detection method includes the following steps of: a step (A) of bringing a biological sample into contact with an oxygen sensor bound to a first molecule that specifically binds to a target substance; a step (B) of bringing the biological sample into contact with a first solid phase support that holds a second molecule and an oxygen-consuming enzyme, the second molecule specifically binding to the target substance; and a step (C) of acquiring information generated from the oxygen sensor by the steps (A) and (B).
    Type: Application
    Filed: January 8, 2019
    Publication date: January 7, 2021
    Inventors: HIROYUKI HOSOKAWA, TOMOTERU ABE
  • Publication number: 20200330989
    Abstract: There is provided a microfluidic device for capturing particles comprising a particle capturing chamber (100) including at least: a particle capturing unit (101) including one of at least one well (106) or at least one through hole (108); and a particle capturing channel unit (102) used for capturing a particle in the well or with the through hole, in which the particle is captured in the well or with the through hole by being sucked, via the particle capturing channel unit, in a direction opposite to a direction (114) on which the particle settles. Such a configuration has for result that the particles that are not captured in the well or with the through hole are prevented from staying in the vicinity of the well or the through hole of the particle capturing unit when suction is stopped.
    Type: Application
    Filed: September 6, 2018
    Publication date: October 22, 2020
    Applicant: Sony Corporation
    Inventors: Shin Masuhara, Kensuke Kojima, Hiroyuki Hosokawa, Yoshiaki Kato, Marcaurele Brun, Toshio Watanabe
  • Patent number: 10493529
    Abstract: Provided is a hard sintered body which exhibits excellent high temperature oxidation resistance and has a high hardness at a high temperature. In the hard sintered body, a binder phase is contained at from 8.8 to 34.4 mol % and the balance is composed of a hard phase and inevitable impurities. The binder phase contains iron aluminide containing FeAl as a main component and alumina that is dispersed in iron aluminide and has a particle size of 1 ?m or less. The hard phase is composed of at least one kind selected from carbides, nitrides, carbonitrides and borides of Group 4 metals, Group 5 metals and Group 6 metals in the periodic table, and solid solutions of these.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: December 3, 2019
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Koji Shimojima, Ryouichi Furushima, Hiroyuki Hosokawa, Kiyotaka Katou, Akihiro Matsumoto
  • Patent number: 10420795
    Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n-NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group. The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: September 24, 2019
    Assignee: Seikagaku Corporation
    Inventors: Hiroyuki Hosokawa, Sooyeol Lim, Junko Takamura
  • Publication number: 20190002543
    Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Applicant: National University Corporation Chiba University
    Inventors: Toshinori Nakayama, Hiroyuki Hosokawa, Koji Tokoyoda, Koji Hayashizaki, Akane Suzuki
  • Patent number: 10100107
    Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: October 16, 2018
    Assignee: National University Corporation Chiba University
    Inventors: Toshinori Nakayama, Hiroyuki Hosokawa, Koji Tokoyoda, Koji Hayashizaki, Akane Suzuki
  • Publication number: 20170334982
    Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 23, 2017
    Applicant: National University Corporation Chiba University
    Inventors: Toshinori Nakayama, Hiroyuki Hosokawa, Koji Tokoyoda, Koji Hayashizaki, Akane Suzuki
  • Publication number: 20170304898
    Abstract: Provided is a hard sintered body which exhibits excellent high temperature oxidation resistance and has a high hardness at a high temperature. In the hard sintered body, a binder phase is contained at from 8.8 to 34.4 mol % and the balance is composed of a hard phase and inevitable impurities. The binder phase contains iron aluminide containing FeAl as a main component and alumina that is dispersed in iron aluminide and has a particle size of 1 ?m or less. The hard phase is composed of at least one kind selected from carbides, nitrides, carbonitrides and borides of Group 4 metals, Group 5 metals and Group 6 metals in the periodic table, and solid solutions of these.
    Type: Application
    Filed: October 2, 2015
    Publication date: October 26, 2017
    Applicant: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Koji SHIMOJIMA, Ryouichi FURUSHIMA, Hiroyuki HOSOKAWA, Kiyotaka KATOU, Akihiro MATSUMOTO
  • Patent number: 9758574
    Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: September 12, 2017
    Assignee: National University Corporation Chiba University
    Inventors: Toshinori Nakayama, Hiroyuki Hosokawa, Koji Tokoyoda, Koji Hayashizaki, Akane Suzuki
  • Publication number: 20170080014
    Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n-NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group. The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Hiroyuki Hosokawa, Sooyeol Lim, Junko Oda
  • Patent number: 9579342
    Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n-NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group. The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: February 28, 2017
    Assignee: Seikagaku Corporation
    Inventors: Hiroyuki Hosokawa, Sooyeol Lim, Junko Takamura
  • Publication number: 20160102139
    Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
    Type: Application
    Filed: May 30, 2014
    Publication date: April 14, 2016
    Inventors: Toshinori NAKAYAMA, Hiroyuki HOSOKAWA, Koji TOKOYODA, Koji HAYASHIZAKI, Akane SUZUKI
  • Publication number: 20140350239
    Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n-NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group. The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.
    Type: Application
    Filed: August 5, 2014
    Publication date: November 27, 2014
    Inventors: Hiroyuki Hosokawa, Sooyeol Lim, Junko Oda
  • Patent number: 8828969
    Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n—NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: September 9, 2014
    Assignee: Seikagaku Corporation
    Inventors: Hiroyuki Hosokawa, Sooyeol Lim, Junko Oda
  • Patent number: 8314776
    Abstract: [Problems] A highly convenient maintenance screen needs to be displayed on a display panel when performing a maintenance while considering a correlation between a plurality of processing chambers. [Means for Solving the Problems] Since task buttons are displayed on a second display region 312 by arranging them from the left in an order of a time sequence in which each task button has been clicked, a highly convenient maintenance screen can be displayed on a touch panel 300 when performing a maintenance.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: November 20, 2012
    Assignee: Tokyo Electron Limited
    Inventors: Hiroyuki Hosokawa, Ryoji Sakai, Masashi Okuyama
  • Publication number: 20120142629
    Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n—NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group. The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.
    Type: Application
    Filed: August 13, 2010
    Publication date: June 7, 2012
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Hiroyuki Hosokawa, Sooyeol Lim, Junko Oda
  • Publication number: 20090225048
    Abstract: [Problems] A highly convenient maintenance screen needs to be displayed on a display panel when performing a maintenance while considering a correlation between a plurality of processing chambers. [Means for Solving the Problems] Since task buttons are displayed on a second display region 312 by arranging them from the left in an order of a time sequence in which each task button has been clicked, a highly convenient maintenance screen can be displayed on a touch panel 300 when performing a maintenance.
    Type: Application
    Filed: May 15, 2007
    Publication date: September 10, 2009
    Applicant: TOKYO ELECTRON LIMITED
    Inventors: Hiroyuki Hosokawa, Ryoji Sakai, Masashi Okuyama
  • Patent number: D589976
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: April 7, 2009
    Assignee: Tokyo Electron Limited
    Inventors: Hiroyuki Hosokawa, Ryoji Sakai, Yoshikazu Ishikawa, Masashi Okuyama
  • Patent number: D593127
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: May 26, 2009
    Assignee: Tokyo Electron Limited
    Inventors: Hiroyuki Hosokawa, Ryoji Sakai, Masashi Okuyama